Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach

被引：42

作者：

Iglesias, Pedro ^{[1
]}

机构：

[1] Hosp Ramon & Cajal, Dept Endocrinol, Ctra Colmenar,Km 9-100, E-28034 Madrid, Spain

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2018年 / 47卷

关键词：

Cancer; Immunotherapy; Endocrinopathies; Hypophysitis; Thyroiditis; Adrenalitis; Type; 1; diabetes; IPILIMUMAB; MELANOMA; BLOCKADE; ANTIBODIES; NIVOLUMAB; CTLA-4;

D O I：

10.1016/j.ejim.2017.08.019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cancer immunotherapy has proven to be effective in a wide variety of tumors. The use of immune checkpoint blocking monoclonal antibodies has become a standard treatment regimen in some of them as advanced melanoma. However, given the mechanism of action, its use may be associated with immune-related adverse events that may complicate the clinical course and prognosis of patients. Among these are autoimmune endocrine adverse effects, such as hypophysitis, hypo and hyperthyroidism, and adrenal insufficiency. This review focuses on the most relevant and new aspects related to the incidence, clinical presentation, diagnosis and treatment of these adverse effects associated with different types of immune checkpoint inhibitors in cancer immunotherapy. (c) 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

引用

页码：6 / 13

页数：8

共 93 条

[1] Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis [J].

Abdel-Rahman, Omar ;

ElHalawani, Hesham ;

Fouad, Mona .

FUTURE ONCOLOGY, 2016, 12 (03) :413-425

[2] Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma [J].

Albarel, Frederique ;

Gaudy, Caroline ;

Castinetti, Frederic ;

Carre, Tiphaine ;

Morange, Isabelle ;

Conte-Devolx, Bernard ;

Grob, Jean-Jacrues ;

Brue, Thierry .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (02) :195-204

[3] Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial [J].

Armand, Philippe ;

Nagler, Arnon ;

Weller, Edie A. ;

Devine, Steven M. ;

Avigan, David E. ;

Chen, Yi-Bin ;

Kaminski, Mark S. ;

Holland, H. Kent ;

Winter, Jane N. ;

Mason, James R. ;

Fay, Joseph W. ;

Rizzieri, David A. ;

Hosing, Chitra M. ;

Ball, Edward D. ;

Uberti, Joseph P. ;

Lazarus, Hillard M. ;

Mapara, Markus Y. ;

Gregory, Stephanie A. ;

Timmerman, John M. ;

Andorsky, David ;

Or, Reuven ;

Waller, Edmund K. ;

Rotem-Yehudar, Rinat ;

Gordon, Leo I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (33) :4199-4206

[4] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].

Ascierto, Paolo A. ;

Del Vecchio, Michele ;

Robert, Caroline ;

Mackiewicz, Andrzej ;

Chiarion-Sileni, Vanna ;

Arance, Ana ;

Lebbe, Celeste ;

Bastholt, Lars ;

Hamid, Omid ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Garbe, Claus ;

Loquai, Carmen ;

Dreno, Brigitte ;

Thomas, Luc ;

Grob, Jean-Jacques ;

Liszkay, Gabriella ;

Nyakas, Marta ;

Gutzmer, Ralf ;

Pikiel, Joanna ;

Grange, Florent ;

Hoeller, Christoph ;

Ferraresi, Virginia ;

Smylie, Michael ;

Schadendorf, Dirk ;

Mortier, Laurent ;

Svane, Inge Marie ;

Hennicken, Delphine ;

Qureshi, Anila ;

Maio, Michele .

LANCET ONCOLOGY, 2017, 18 (05) :611-622

[5]

Atkins MB, 2017, ANN ONCOL

[6] Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 [J].

Attia, P ;

Phan, GQ ;

Maker, AV ;

Robinson, MR ;

Quezado, MM ;

Yang, JC ;

Sherry, RM ;

Topalian, SL ;

Kammula, US ;

Royal, RE ;

Restifo, NP ;

Haworth, LR ;

Levy, C ;

Mavroukakis, SA ;

Nichol, G ;

Yellin, MJ ;

Rosenberg, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6043-6053

[7] Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma [J].

Azmat, Umal ;

Liebner, David ;

Joehlin-Price, Amy ;

Agrawal, Amit ;

Nabhan, Fadi .

CASE REPORTS IN ENDOCRINOLOGY, 2016, 2016

[8] Ipilimumab-Induced Adrenalitis A Possible Pitfall in 18F-FDG-PET/CT [J].

Bacanovic, Sara ;

Burger, Irene A. ;

Stolzmann, Paul ;

Hafner, Juerg ;

Huellner, Martin W. .

CLINICAL NUCLEAR MEDICINE, 2015, 40 (11) :e518-e519

[9] Hyponatremia associated with Ipilimumab-induced hypophysitis [J].

Barnard, Zachary R. ;

Walcott, Brian P. ;

Kahle, Kristopher T. ;

Nahed, Brian V. ;

Coumans, Jean Valery .

MEDICAL ONCOLOGY, 2012, 29 (01) :374-377

[10] Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects [J].

Bellastella, Giuseppe ;

Maiorino, Maria Ida ;

Bizzarro, Antonio ;

Giugliano, Dario ;

Esposito, Katherine ;

Bellastella, Antonio ;

De Bellis, Annamaria .

PITUITARY, 2016, 19 (06) :625-642

← 1 2 3 4 5 6 7 8 9 10 →